Literature DB >> 15172426

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

James H O'Keefe1, Loren Cordain, William H Harris, Richard M Moe, Robert Vogel.   

Abstract

The normal low-density lipoprotein (LDL) cholesterol range is 50 to 70 mg/dl for native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals (all of whom do not develop atherosclerosis). Randomized trial data suggest atherosclerosis progression and coronary heart disease events are minimized when LDL is lowered to <70 mg/dl. No major safety concerns have surfaced in studies that lowered LDL to this range of 50 to 70 mg/dl. The current guidelines setting the target LDL at 100 to 115 mg/dl may lead to substantial undertreatment in high-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172426     DOI: 10.1016/j.jacc.2004.03.046

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  118 in total

Review 1.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.

Authors:  Ashwin Durairaj; Alberto Sabates; Jonathan Nieves; Brian Moraes; Seth Baum
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

2.  High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

Review 3.  Statin therapy: is the percent reduction or the attained low-density lipoprotein cholesterol level more important?

Authors:  Tracie C Collins; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

4.  Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

Review 5.  Long term medical treatment of stable coronary disease.

Authors:  David M Shavelle
Journal:  Heart       Date:  2007-11       Impact factor: 5.994

6.  New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2007-02

7.  Another inconvenient truth: combining the risks from obesity and metabolic syndrome with global warming.

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

8.  Statins and primary prevention: is all the evidence in?

Authors:  Shirya Rashid; Gordon A Francis
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

Review 9.  Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.

Authors:  Howard S Weintraub
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 10.  The role of early LDL lowering to prevent the onset of atherosclerotic disease.

Authors:  Brian A Ference; Nitin Mahajan
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.